Preclinical data suggest improved complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity compared with rituximab in variety of lymphomas. In early clinical trials, ofatumumab demonstrated single-agent activity against chronic lymphocytic leukemia (CLL) and a number of histologies of B-cell non-Hodgkin’s lymphomas. It was approved by the US Food and Drug Administration for the treatment of CLL that is resistant to both fludarabine and alemtuzumab. In In early clinical trials, ofatumumab demonstrated single-agent activity against CLL and a number of histologies of B-cell NHL.
Not much is known about its effectiveness for mantle cell lymphoma. Preclinical comparisons to rituximab show some parameters in which ofamutumab appears superior to rituxumab and others in which it does not. a review on the use of ofatumumab for the treatment of B-cell malignancies, Cheson noted that pre-clinical data suggest improved complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity of ofatumumab compared with rituximab. Ofatumumab is a clinical trial for Mantle cell lymphoma: Ofatumumab With or WithouteBendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant. This study is being done to understand how to treat Mantle Cell Lymphoma (MCL). A recent study was presented by M. Magni in an abstract form at the 2011 ASH conference. It found that chemotherapy with bendamustine and ofatumumab appears generally safe and well tolerated to date in MCL patients aged ≥ 65 years requiring treatment. Preliminary data about efficacy are encouraging: accrual is ongoing for further evaluation.
Michele Magni at al, Safety, Tolerability and Activity of Ofatumumab, Bendamustine and Dexamethasone Combination As First-Line Treatment of Mantle-Cell Lymphoma in the Elderly: A Multicenter Study Program: Oral and Poster Abstracts Session: 624. Lymphoma – Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster I Saturday, December 10, 2011, 5:30 PM-7:30 PM Hall GH (San Diego Convention Center)
Cheson BD. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J Clin Oncol. 2010;28(21):3525-3530.
Nathan H. Fowler, et al, Results of a Phase II Study with Bendamustine and Ofatumumab in Untreated Indolent B-Cell Non-Hodgkin’s Lymphoma ASCO Monday, December 12, 2011, a778
For Lay version see here
Bendamustine and Rituxan for Mantle Cell Lymphoma here